Continous Renal Replacement Therapy With the CARPEDIEM® in a French National Cohort of 25 Neonates and Small Infants

Centre Hospitalier Universitaire de Nice25 enrolled

Overview

Historically, CKRT and hemodialysis were performed in small infants and newborns with devices developed for adults with high rates of complications and mortality. We aim to retrospectively report the first multicenter French experience of CARPEDIEM® use and evaluate the efficacy, feasibility, outcomes, and technical considerations of this new device in a population of neonates and small infant. Compared to adult's device continuous renal replacement therapy with an adapted machine allowed successful blood purification without severe complications even in low birth weight neonates.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypoxic-Ischemic Encephalopathy Sepsis Kidney Diseases Metabolic Disease Twin to Twin Transfusion Syndrome Cardiac Disease Pulmonary Disease

Interventions

CARPEDIENDEVICE

Continuous renal replacement therapy

Eligibility

Sex: ALLMin age: 0 YearsMax age: 3 Years

Medical Language ↔ Plain English

Inclusion criteria: * Children and neonates including premature and low birth weight neonates * Have a diagnosis of acute kidney injury, end stage renal disease, metabolic disease, electrolyte abnormality * Require renal replacement therapy Exclusion Criteria: -Renal replacement therapy with another device than Carpediem machine

Locations (1)

CHU de Nice

Nice, France

Outcomes

Primary Outcomes

Survival

Time frame: 3 years

Serum creatinine

Time frame: 3 years

Serum potassium

Time frame: 3 years

Blood urea nitrogen

Time frame: 3 years

Ammonia levels

Time frame: 3 years

Secondary Outcomes

Ultrafiltration flow

the substitution range with the effluent volume in ml/kg/h ( compared to the KDIGO recommend of 25-35 ml/kg/h)

Time frame: 3 years

Blood flow

The range of blood flow in ml/kg/min ( compared to the recommend blood flow of 3-10 ml/kg/min).

Time frame: 3 years

Anticoagulation

The dose of continuous heparin anticoagulation in UI/Kg/h to prevent circuit clotting.

Time frame: 3 years

Number of sessions

Time frame: 3 years

Time of treatments

Time frame: 3 years

CKRT modality

Time frame: 3 years

Vascular access

The localization of a vascular access ( intern jugular, subclavian, umbilical or femoral).

Time frame: 3 years

Priming circuit

The priming circuit ( normal salin, albumin, Isofundin or packed red blood cells).

Time frame: 3 years

Size of the circuit

Time frame: 3 years

Death

Time frame: 3 years

Clotting circuit and other dysfunction circuit

* Dysfunction circuit included cathether dysfunction, pressure dysfucntion and failure restitution * Complications of an extra corporel therapy including hypotension, thrombocytopenia and clotting circuit.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.